What is Galatek?
Founded in 2016, Galatek operates at the intersection of advanced robotics and artificial intelligence. The company provides a comprehensive suite of automated solutions, most notably its Abio software platform, which integrates electronic lab notebooks, LIMS, and SDMS into a unified, AI-driven ecosystem. In the life sciences domain, Galatek facilitates breakthroughs in synthetic biology, NGS sequencing, and organoid research through high-throughput screening platforms. Simultaneously, the firm addresses the rigorous demands of the semiconductor industry by delivering advanced packaging solutions, including deep learning-based optical inspection and precision wafer dicing equipment. This diversified market position allows Galatek to maintain resilience while driving innovation in two of the most capital-intensive and technically demanding sectors of the global economy.
How much funding has Galatek raised?
Galatek has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2025): $30M, investors not publicly disclosed
Key Investors in Galatek
Galatek
Undisclosed investor participating in the funding round.
What's next for Galatek?
With the recent influx of capital, Galatek is expected to prioritize the scaling of its R&D centers and the enhancement of its global supply chain. The strategic roadmap likely involves deepening the integration of its Abio software across new pharmaceutical and semiconductor manufacturing facilities. By focusing on localized service delivery models in key markets like Japan and the United States, the company aims to solidify its role as an essential infrastructure provider. Future growth will likely be defined by the continued refinement of its deep learning algorithms, ensuring that its automated systems remain at the forefront of precision engineering and scientific discovery.
See full Galatek company page
